Lupin to develop inhalers with near-zero global warming potential propellants

Lupin's R&D teams are working on products with a near-zero global warming potential propellant

GlaxoSmithKline Pharmaceuticals Q2 FY25 revenue crosses Rs. 1,000 Cr

The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market

Lupin appoints Claus Jepsen as President, Global Specialty

AstraZeneca advances science of infectious disease protection at IDWeek 2024

Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19

Indian drug regulator recommends Wockhardt's Miqnaf for treatment of CABP

Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO

Baxter launches nextgen airway clearance system

Developed in consultation with clinicians and patients for an enhanced user experience

AstraZeneca Pharma India to launch Palivizumab (Synagis) in October 2024

Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease

Wockhardt wins “BIRAC Innovator Award 2024”

The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia

Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast

ALS patients experience neuroinflammation and rapid neurodegeneration

Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform

Agreement further expands Aptar Pharma’s leading respiratory portfolio